TuesdayApr 08, 2008 9:05 am

OTCPicks Featured Company: Expert Group, Inc. (EXPT.PK) Provides March 2008 Financial Numbers

Expert Group, Inc. (OTC: EXPT) recently announced their financial figures for the month of March, in which the company originated $1.3 million in loans, bringing a $50,000 net profit to the company. These numbers do not include payroll for the recent addition of ten new loan officers during the month of March, who were added to take advantage of Expert Group's building momentum. The company’s stock was up 130.00% on Monday. A company spokesperson commented, "We are understandably pleased to be able to announce the realization of net profitability. However, as far as we are concerned, this is just a…

Continue Reading

TuesdayApr 08, 2008 8:45 am

Lebed.biz Featured Company: Pluristem Therapeutics Inc. (PSTI)

Pluristem Therapeutics Inc. (PSTI) is a leading bio-therapeutics company with research and manufacturing facilities located in Israel. The company derives its products from stem cells which are obtained from the placenta, a non-controversial source unlike embryonic stem cells. The company is seeking to commercialize these non-personalized stem-cell therapy products for the treatment of certain, severe autoimmune disorders. After obtaining these stem cells, Pluristem literally grows its product in a proprietary PLURI-X bio-reactor and the product is stored "ready-to-use". The bio-reactor mimics the natural microstructure of bone marrow so supplemental growth materials are not required. The company's initial product, called PLX-I,…

Continue Reading

TuesdayApr 08, 2008 8:41 am

Communicate.com, Inc. (CMNN.OB) – Made-Over to Live Current Media Inc.

There are times when a company feels the need to do a drastic makeover in order to take its business to the next level. It could be that the old way of doing business is at a standstill and, in order to move the company into the future, changes are necessary. For some industry experts, the dot-com industry bubble ended with the new millennium. But some companies like Communicate.com, who still see the Internet as a way of generating profit, are changing the way they do business. Communicate.com builds, owns and operates some of the most powerful and engaging content…

Continue Reading

TuesdayApr 08, 2008 8:18 am

StockGuru Blog: NextGen Bioscience (NXGB) and Its Work on Infectious Diseases

NextGen Bioscience, Inc. is a drug development biotechnology company focused on the identification, evaluation and acquisition of drug candidates for treatment and prevention of cancers and infectious diseases in human beings. “NextGen” leverages cutting-edge research collaborations to achieve breakthroughs in anti-cancer treatments, and then licenses these patented drug product candidates to Big Pharmaceutical companies. NextGen’s business model is to acquire promising new patented technologies in the fields of cancer and infectious disease, to add significant value to these by advancing them through toxicological assessment or Phase I clinical trials and then outlicensing the technology to a larger partner who has…

Continue Reading

TuesdayApr 08, 2008 8:01 am

StockGuru Stocks to Watch for Tuesday, April 8, 2008 Featuring NextGen Bioscience, China Voice, Sports Pouch Beverage and KCM Holdings

NextGen Bioscience, Inc. (OTC: NXGB) NextGen Bioscience, Inc. (OTC: NXGB) - Monday’s shares closed down 2.44% to $0.40. 53,700 shares were traded. NextGen Bioscience, Inc. announced recently it is in collaboration negotiations with SymbioTec GmbH, a German company that has developed and patented an effective and commercially attractive cancer-fighting compound. The two companies have signed a Letter of Intent to come to a collaboration agreement. Konstantinos Kardiasmenos, CEO of NextGen, stated, “A strategic collaboration with SymbioTec would be a significant step in propelling both companies forward in our mutual goals to satisfy the lucrative and unmet demand for novel approaches…

Continue Reading

TuesdayApr 08, 2008 8:00 am

StockGuru News: NextGen (NXGB) Acquires Patent Application for Breast Cancer Stem Cell Treatment

LONDON, UNITED KINGDOM–Apr 8, 2008 — NextGen Bioscience, Inc., a biotechnology company that develops novel therapeutic proteins that disrupt the advance of life-threatening cancers, today announced it has acquired use, commercialisation and ownership rights of a patent application for the treatment of cancer from Oxon Life Science Inc. The patent application describes an improved method of identifying and purifying undifferentiated stem cells from solid breast carcinomas that are normally resistant to conventional therapies. The cancer stem cell is typically represented as a distinct population of cells within a tumour which may remain even if the rest of the tumour is…

Continue Reading

Market Basics

New to the micro-cap markets?Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks and learn how to protect yourself.

The Basics

Newsletter Publishers

Have an up and coming newsletter and want to be included in our coverage list? Looking to get more coverage and grow subscriptions? Register for coverage.

Register

Public Companies

Are you a Small-Cap / Micro-Cap company looking for coverage? We'd love to hear from you. Fill out our quick contact form or send us a text.

Get Covered